This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Johnen G, Chapman SJ, Cookson WO, Musk AW, Lee YC. Benign asbestos pleural diseases. Curr Opin Pulm Med 2003; 9: 266-71. doi: 10.1097/00063198-200307000-00004JohnenGChapmanSJCooksonWOMuskAWLeeYCBenign asbestos pleural diseasesCurr Opin Pulm Med200392667110.1097/00063198-200307000-00004Open DOISearch in Google Scholar
IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: asbestos. IARC Monogr Eval Carcinog Risk Chem Man 1977; 14: 1-106. PMID: 863456IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: asbestosIARC Monogr Eval Carcinog Risk Chem Man1977141106PMID: 863456Search in Google Scholar
Robinson BWS, Lake RA. Medical progress – advances in malignant mesothelioma. N Engl J Med 2005; 353: 1591-603. doi: 10.1056/NEJMra050152RobinsonBWSLakeRAMedical progress – advances in malignant mesotheliomaN Engl J Med2005353159160310.1056/NEJMra050152Open DOISearch in Google Scholar
Kovac V, Zwitter M, Zagar T. Improved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patients. Radiol Oncol 2012; 46: 136-44. doi: 10.2478/ v10019-012-0032-0KovacVZwitterMZagarTImproved survival after introduction of chemotherapy for malignant pleural mesothelioma in Slovenia: population-based survey of 444 patientsRadiol Oncol2012461364410.2478/v10019-012-0032-0Open DOISearch in Google Scholar
Damhuis RA, Schroten C, Burgers JA. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur Respir J 2012; 40: 185-9. doi: 10.1183/09031936.00153611DamhuisRASchrotenCBurgersJAPopulation-based survival for malignant mesothelioma after introduction of novel chemotherapyEur Respir J201240185910.1183/09031936.00153611Open DOISearch in Google Scholar
Helland A, Solberg S, Brustugun OT. Incidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 cases. J Thorac Oncol 2012; 7: 1858-61. doi: 10.1097/JTO.0b013e318275b346HellandASolbergSBrustugunOTIncidence and survival of malignant pleural mesothelioma in norway: a population-based study of 1686 casesJ Thorac Oncol2012718586110.1097/JTO.0b013e318275b346Open DOISearch in Google Scholar
Tomasetti M, Santarelli L. Biomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic application. Cancers 2010; 2: 523-48. doi: 10.3390/cancers2020523TomasettiMSantarelliLBiomarkers for early detection of malignant mesothelioma: diagnostic and therapeutic applicationCancers201025234810.3390/cancers2020523Open DOISearch in Google Scholar
Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-6. doi: 10.1016/S0140-6736(03)14794-0RobinsonBWCreaneyJLakeRNowakAMuskAWde KlerkNet alMesothelin-family proteins and diagnosis of mesotheliomaLancet20033621612610.1016/S0140-6736(03)14794-0Open DOISearch in Google Scholar
Husain AN, Colby TV, Ordóñez NG, Allen TC, Attanoos RL, Beasley MB, et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med 2018; 14: 89-108. doi: 10.5858/ arpa.2017-0124-RAHusainANColbyTVOrdóñezNGAllenTCAttanoosRLBeasleyMBet alGuidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest GroupArch Pathol Lab Med2018148910810.5858/arpa.2017-0124-RA28686500Open DOISearch in Google Scholar
Ordonez NG. Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003; 16: 192-7. doi: 10.1097/01. MP.0000056981.16578.C3OrdonezNGValue of mesothelin immunostaining in the diagnosis of mesotheliomaMod Pathol200316192710.1097/01.MP.0000056981.16578.C312640097Open DOISearch in Google Scholar
Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, et al. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev 2010; 19: 2238-46. doi: 10.1158/1055-9965.EPI-10-0346CreaneyJOlsenNJBrimsFDickIMMuskAWde KlerkNHet alSerum mesothelin for early detection of asbestos-induced cancer malignant mesotheliomaCancer Epidemiol Biomarkers Prev20101922384610.1158/1055-9965.EPI-10-034620651076Open DOISearch in Google Scholar
Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. J Clin Oncol 2012; 30: 1541-9. doi: 10.1200/JCO.2011.39.6671HollevoetKReitsmaJBCreaneyJGrigoriuBDRobinsonBWScherpereelAet alSerum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysisJ Clin Oncol2012301541910.1200/JCO.2011.39.6671338312222412141Open DOISearch in Google Scholar
Hollevoet K, Van Cleemput J, Thimpont J, De Vuyst P, Bosquee L, Nackaerts K, et al. Serial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort study. J Thorac Oncol 2011; 6: 889-95. doi: 10.1097/JTO.0b013e31820db377HollevoetKVanCleemput JThimpontJDe VuystPBosqueeLNackaertsKet alSerial measurements of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort studyJ Thorac Oncol201168899510.1097/JTO.0b013e31820db37721358346Open DOISearch in Google Scholar
Cui A, Jin XG, Zhai K, Tong ZH, Shi HZ. Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis. BMJ open 2014; 4: e004145. doi: 10.1136/bmjopen-2013-004145CuiAJinXGZhaiKTongZHShiHZDiagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysisBMJ open20144e00414510.1136/bmjopen-2013-004145393965124566531Open DOISearch in Google Scholar
Hassan R, Thomas A, Alewine C, Le DT, Jaffee EM, Pastan I. Mesothelin immunotherapy for cancer: ready for prime time? J Clin Oncol 2016; 34: 4171-9. doi: 10.1200/JCO.2016.68.3672HassanRThomasAAlewineCLeDTJaffeeEMPastanIMesothelin immunotherapy for cancer: ready for prime time?J Clin Oncol2016344171910.1200/JCO.2016.68.3672547781927863199Open DOISearch in Google Scholar
Gillezeau C, van Gerwen M, Ramos J, Liu B, Flores R, Taioli E. Biomarkers for malignant pleural mesothelioma: a meta-analysis. Carcinogenesis 2019. doi: 10.1093/carcin/bgz103GillezeauCvan GerwenMRamosJLiuBFloresRTaioliEBiomarkers for malignant pleural mesothelioma: a meta-analysisCarcinogenesis201910.1093/carcin/bgz10331169881Open DOISearch in Google Scholar
Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, et al. Soluble mesothelin-related protein--a blood test for mesothelioma. Lung Cancer 2005; 49(Suppl 1): S109-11. doi: 10.1016/j.lungcan.2005.03.020RobinsonBWCreaneyJLakeRNowakAMuskAWde KlerkNet alSoluble mesothelin-related protein--a blood test for mesotheliomaLung Cancer200549Suppl 1S1091110.1016/j.lungcan.2005.03.02015950789Open DOISearch in Google Scholar
Tian L, Zeng R, Wang X, Shen C, Lai Y, Wang M, et al. Prognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysis. Oncotarget 2017; 8: 46425-35. doi: 10.18632/oncotarget.17436TianLZengRWangXShenCLaiYWangMet alPrognostic significance of soluble mesothelin in malignant pleural mesothelioma: a meta-analysisOncotarget20178464253510.18632/oncotarget.17436554227828507279Open DOISearch in Google Scholar
He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ, et al. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells. Mol Cancer 2017; 16: 63. doi: 10.1186/ s12943-017-0633-8HeXWangLRiedelHWangKYangYDinuCZet alMesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cellsMol Cancer2017166310.1186/s12943-017-0633-8534878428288645Open DOISearch in Google Scholar
Cristaudo A, Bonotti A, Simonini S, Bruno R, Foddis R. Soluble markers for diagnosis of malignant pleural mesothelioma. Biomark Med 2011; 5: 261-73. doi: 10.2217/bmm.11.18CristaudoABonottiASimoniniSBrunoRFoddisRSoluble markers for diagnosis of malignant pleural mesotheliomaBiomark Med201152617310.2217/bmm.11.1821473730Open DOISearch in Google Scholar
Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M. Soluble mesothelin-related peptides levels in patients with malignant mesothelioma. Dis Markers 2012; 32: 123-31. doi: 10.3233/DMA-2011-0866FrankoADolzanVKovacVArnericNDodic-FikfakMSoluble mesothelin-related peptides levels in patients with malignant mesotheliomaDis Markers2012321233110.3233/DMA-2011-0866382670522377706Open DOISearch in Google Scholar
de Fonseka D, Arnold DT, Stadon L, Morley A, Keenan E, Darby M, et al. A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma. BMC Cancer 2018; 18: 199. doi: 10.1186/ s12885-018-4113-3de FonsekaDArnoldDTStadonLMorleyAKeenanEDarbyMet alA prospective study to investigate the role of serial serum mesothelin in monitoring mesotheliomaBMC Cancer20181819910.1186/s12885-018-4113-3581638929454314Open DOISearch in Google Scholar
Linch M, Gennatas S, Kazikin S, Iqbal J, Gunapala R, Priest K, et al. A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice. BMC Cancer 2014; 14: 674. doi: 10.1186/1471-2407-14-674LinchMGennatasSKazikinSIqbalJGunapalaRPriestKet alA serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practiceBMC Cancer20141467410.1186/1471-2407-14-674418277625227779Open DOISearch in Google Scholar
Li ZQ, Verch T, Allard WJ. MESOMARK((R)) in vitro diagnostic test for mesothelioma. Expert Opin Med Diagn 2007; 1: 137-42. doi: 10.1517/17530059.1.1.137LiZQVerchTAllardWJMESOMARK((R)) in vitro diagnostic test for mesotheliomaExpert Opin Med Diagn200711374210.1517/17530059.1.1.13723489276Open DOISearch in Google Scholar
Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, et al. Two novel polymorphisms in 5’ flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels. Int J Biol Markers 2011; 26: 117-23. doi: 10.5301/JBM.2011.8332CristaudoAFoddisRBonottiASimoniniSVivaldiAGuglielmiGet alTwo novel polymorphisms in 5’ flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levelsInt J Biol Markers2011261172310.5301/JBM.2011.833221574151Open DOISearch in Google Scholar
De Santi C, Pucci P, Bonotti A, Melaiu O, Cipollini M, Silvestri R, et al. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals. Occup Environ Med 2017; 74: 456-63. doi: 10.1136/oemed-2016-104024De SantiCPucciPBonottiAMelaiuOCipolliniMSilvestriRet alMesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individualsOccup Environ Med2017744566310.1136/oemed-2016-10402428343162Open DOISearch in Google Scholar
Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, et al. Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein. Occup Environ Med 2010; 67: 233-6. doi: 10.1136/oem.2009.049205CristaudoAFoddisRBonottiASimoniniSVivaldiAGuglielmiGet alPolymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related proteinOccup Environ Med201067233610.1136/oem.2009.04920519858537Open DOISearch in Google Scholar
Garritano S, De Santi C, Silvestri R, Melaiu O, Cipollini M, Barone E, et al. A common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy people. J Thorac Oncol 2014; 9: 1662-8. doi: 10.1097/JTO.0000000000000322GarritanoSDe SantiCSilvestriRMelaiuOCipolliniMBaroneEet alA common polymorphism within MSLN affects miR-611 binding site and soluble mesothelin levels in healthy peopleJ Thorac Oncol201491662810.1097/JTO.000000000000032225436799Open DOISearch in Google Scholar
Tossavainen A. Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health 1997; 23: 311-6. doi: 10.5271/sjweh.226TossavainenAAsbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attributionScand J Work Environ Health199723311610.5271/sjweh.226Open DOISearch in Google Scholar
American Thoracic Sociaty Document. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med 2004; 170: 691-715. doi: 10.1164/rccm.200310-1436STAmerican Thoracic Sociaty Document. Diagnosis and initial management of nonmalignant diseases related to asbestosAm J Respir Crit Care Med200417069171510.1164/rccm.200310-1436ST15355871Open DOISearch in Google Scholar
Ferris BG. Epidemiology Standardization Project (American Thoracic Society). Am Rev Respir Dis 1978; 118: 1-120. PMID: 742764FerrisBGEpidemiology Standardization Project (American Thoracic Society)Am Rev Respir Dis19781181120PMID: 742764Search in Google Scholar
Dodic Fikfak M, Kriebel D, Quinn MM, Eisen EA, Wegman DH. A case control study of lung cancer and exposure to chrysotile and amphibole at a slovenian asbestos-cement plant. Ann Occup Hyg 2007; 51: 261-8. doi: 10.1093/ annhyg/mem003Dodic FikfakMKriebelDQuinnMMEisenEAWegmanDHA case control study of lung cancer and exposure to chrysotile and amphibole at a slovenian asbestos-cement plantAnn Occup Hyg200751261810.1093/annhyg/mem00317351264Open DOISearch in Google Scholar
Bruno F, Baratti D, Martinetti A, Morelli D, Sottotetti E, Bonini C, et al. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study. Ejso-Eur J Surg Onc 2018; 44: 792-8. doi: 10.1016/j.ejso.2018.02.010BrunoFBarattiDMartinettiAMorelliDSottotettiEBoniniCet alMesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary studyEjso-Eur J Surg Onc201844792810.1016/j.ejso.2018.02.01029503128Open DOISearch in Google Scholar
Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, et al. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med 2009; 179: 950-4. doi: 10.1164/rccm.200807-1125OCGrigoriuBDChahineBVachaniAGeyTContiMStermanDHet alKinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatmentAm J Respir Crit Care Med2009179950410.1164/rccm.200807-1125OC19201924Open DOISearch in Google Scholar
Arnold DT, De Fonseka D, Hamilton FW, Rahman NM, Maskell NA. Prognostication and monitoring of mesothelioma using biomarkers: a systematic review. Br J Cancer 2017; 116: 731-41. doi: 10.1038/bjc.2017.22ArnoldDTDe FonsekaDHamiltonFWRahmanNMMaskellNAPrognostication and monitoring of mesothelioma using biomarkers: a systematic reviewBr J Cancer20171167314110.1038/bjc.2017.22535592728170372Open DOISearch in Google Scholar
Fontana V, Vigani A, Pistillo MP, Giannoni U, Rosemberg I, Canessa PA, et al. The correlation of serum mesothelin level with pleural thickness in malignant pleural mesothelioma makes it a valuable tool for monitoring tumor progression. J Thorac Oncol 2019; 14: e92-e4. doi: 10.1016/j. jtho.2018.12.026FontanaVViganiAPistilloMPGiannoniURosembergICanessaPAet alThe correlation of serum mesothelin level with pleural thickness in malignant pleural mesothelioma makes it a valuable tool for monitoring tumor progressionJ Thorac Oncol201914e92e410.1016/j.jtho.2018.12.02631027749Open DOISearch in Google Scholar
Park EK, Wilson D, Yates DH. A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels. Clin Chem Lab Med 2012; 50: 2199-204. doi: 10.1515/cclm-2012-0314ParkEKWilsonDYatesDHA predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levelsClin Chem Lab Med201250219920410.1515/cclm-2012-031423093275Open DOISearch in Google Scholar
Filiberti R, Marroni P, Mencoboni M, Mortara V, Caruso P, Cioe A, et al. Individual predictors of increased serum mesothelin in asbestos-exposed workers. Med Oncol 2013; 30: 422. doi: 10.1007/s12032-012-0422-6FilibertiRMarroniPMencoboniMMortaraVCarusoPCioeAet alIndividual predictors of increased serum mesothelin in asbestos-exposed workersMed Oncol20133042210.1007/s12032-012-0422-623277285Open DOISearch in Google Scholar
Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, et al. Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 2012; 367: 1417-27. doi: 10.1056/NEJMoa1115050PassHILevinSMHarbutMRMelamedJChiribogaLDoningtonJet alFibulin-3 as a blood and effusion biomarker for pleural mesotheliomaN Engl J Med201236714172710.1056/NEJMoa1115050376121723050525Open DOISearch in Google Scholar
Kovac V, Dodic-Fikfak M, Arneric N, Dolzan V, Franko A. Fibulin-3 as a bio-marker of response to treatment in malignant mesothelioma. Radiol Oncol 2015; 49: 279-85. doi: 10.1515/raon-2015-0019KovacVDodic-FikfakMArnericNDolzanVFrankoAFibulin-3 as a bio-marker of response to treatment in malignant mesotheliomaRadiol Oncol2015492798510.1515/raon-2015-0019457722526401134Open DOISearch in Google Scholar
Cristaudo A, Bonotti A, Guglielmi G, Fallahi P, Foddis R. Serum mesothelin and other biomarkers: what have we learned in the last decade? J Thorac Dis 2018; 10: S353-9. doi: 10.21037/jtd.2017.10.132CristaudoABonottiAGuglielmiGFallahiPFoddisRSerum mesothelin and other biomarkers: what have we learned in the last decade?J Thorac Dis201810S353910.21037/jtd.2017.10.132583055629507805Open DOISearch in Google Scholar
Creaney J, Robinson BWS. Malignant mesothelioma biomarkers: from discovery to use in clinical practice for diagnosis, monitoring, screening, and treatment. Chest 2017; 152: 143-9. doi: 10.1016/j.chest.2016.12.004CreaneyJRobinsonBWSMalignant mesothelioma biomarkers: from discovery to use in clinical practice for diagnosis, monitoring, screening, and treatmentChest2017152143910.1016/j.chest.2016.12.00428007619Open DOISearch in Google Scholar
Kirschner MB, Cheng YY, Badrian B, Kao SC, Creaney J, Edelman JJ, et al. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol 2012; 7: 1184-91. doi: 10.1097/JTO.0b013e3182572e83KirschnerMBChengYYBadrianBKaoSCCreaneyJEdelmanJJet alIncreased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesotheliomaJ Thorac Oncol2012711849110.1097/JTO.0b013e3182572e8322617246Open DOISearch in Google Scholar
Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, et al. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma. J Thorac Oncol 2011; 6: 1587-93. doi: 10.1097/JTO.0b013e31821e1c08CristaudoABonottiASimoniniSVivaldiAGuglielmiGAmbrosinoNet alCombined serum mesothelin and plasma osteopontin measurements in malignant pleural mesotheliomaJ Thorac Oncol2011615879310.1097/JTO.0b013e31821e1c0821642872Open DOISearch in Google Scholar
Hoda MA, Dong Y, Rozsas A, Klikovits T, Laszlo V, Ghanim B, et al. Circulating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - a multi-institutional study. Eur J Cancer 2016; 63: 64-73. doi: 10.1016/j.ejca.2016.04.018HodaMADongYRozsasAKlikovitsTLaszloVGhanimBet alCirculating activin A is a novel prognostic biomarker in malignant pleural mesothelioma - a multi-institutional studyEur J Cancer201663647310.1016/j.ejca.2016.04.01827288871Open DOISearch in Google Scholar
Foddis R, Bonotti A, Landi S, Fallahi P, Guglielmi G, Cristaudo A. Biomarkers in the prevention and follow-up of workers exposed to asbestos. J Thorac Dis 2018; 10: S360-8. doi: 10.21037/jtd.2017.12.17FoddisRBonottiALandiSFallahiPGuglielmiGCristaudoABiomarkers in the prevention and follow-up of workers exposed to asbestosJ Thorac Dis201810S360810.21037/jtd.2017.12.17583054829507806Open DOISearch in Google Scholar
Santarelli L, Staffolani S, Strafella E, Nocchi L, Manzella N, Grossi P, et al. Combined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesothelioma. Lung Cancer 2015; 90: 457-64. doi: 10.1016/j.lungcan.2015.09.021SantarelliLStaffolaniSStrafellaENocchiLManzellaNGrossiPet alCombined circulating epigenetic markers to improve mesothelin performance in the diagnosis of malignant mesotheliomaLung Cancer2015904576410.1016/j.lungcan.2015.09.02126431916Open DOISearch in Google Scholar
